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Central nervous system (CNS) cancer is a devastating illness with unmet therapeutic needs. Establishing biomarkers that have the 
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interest. Cerebrospinal fluid (CSF) has been extensively targeted for the detection of molecules that might be useful markers for 
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INTRODUCTION
Brain cancers are the leading cause of death by solid tumors 
in children and the cause of morbidity and mortality across 
a wide range of adult individuals.[1,2] The identification of 
biomarkers that could allow diagnosis of brain neoplasms 
and could be informative for cancer spread or monitor 
therapy response is in great demand. Blood analysis for 
novel biomarkers has facilitated the timely diagnosis for 
patients with several malignancies such as prostate and 
breast cancers.[3] However, one of the challenges that 
contributes to the paucity of biomarkers in the serum for 
central nervous system (CNS) malignancies is the blood-
brain barrier, which is thought to prevent the release 
of tumor-specific molecules into the blood circulation. 
Cerebrospinal fluid (CSF) has thus been investigated in the 
search for brain tumor markers.
CSF is a readily accessible body fluid that is reflective 
of the underlying pathological state of the CNS, hence it 
has been widely targeted for biomarker discovery for a 
variety of neurological disorders. The CSF is continuously 
produced and recycled much like blood or lymph.[3] The 
majority of CSF is produced by the choroid plexus located 
on the lateral, third and fourth ventricles. The rate of CSF 
production in humans is 0.3-0.4 mL/min and the total CSF 
volume is 90-150 mL in adults and 65-150 mL in children.[4-6] 
CSF circulates through the ventricles, the cisterns, and the 
subarachnoidal space at the base of the brain, then flows 
over the convexities of the brain and down the length of 
the spinal cord.[5-7] Therefore, CSF is in contact with brain 
tissue and in proximity to most tumor bulks, making it 
an ideal reservoir of tumor-related/secreted molecules.[8] 
It is accessible through lumbar puncture, a little invasive 
procedure. Any cancer cells released by brain cancer bulk or 
molecules that are actively secreted or passively diffused by 
cancer cells are likely to disperse into the CSF and therefore 
can be detected. Hence CSF analysis is considered to be an 
important tool in the evaluation of CNS malignancies. This 
review discusses potential and limitations of CSF analyses 
in brain cancer patients.
DETECTION OF CANCER CELLS IN THE 
CSF
Primary CNS cancers and metastases are often located in 
close proximity to ventricular surfaces or CSF cisterns.[9-11] 
Malignant cells derived from brain cancers reach the 
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leptomeninges by CSF spread or by direct extension 
from the primary tumor itself e.g. medulloblastoma, 
primitive neuroectodermal tumors, germ cell tumors, 
ependymoma, and glioma may be disseminated throughout 
the neuroaxis by the flow of the CSF.[12-14] Table 1 shows 
the particular incidence of malignant leptomeningeal 
involvement in selected primary brain cancers. Currently 
microscopic evaluation of CSF is routinely performed in 
CNS malignancies with frequent leptomeningeal spread, 
such as medulloblastomas, PNET, pineoblastomas, germ-
cell tumors and CNS lymphoma.[15] Cancer therapy and 
prognosis of these groups of brain cancer are crucially 
determined by positive CSF cytology.[13,14]
CSF cytoanalysis
CSF cytology, in which CSF is prepared and examined 
under a microscope to look for cells, is currently considered 
the gold standard for diagnosis of brain cancer with 
leptomeningeal spread and metastatic cancer to the brain.[14] 
To achieve CSF cytology a sample can be obtained at the time 
of tumor surgery or by lumbar or intracerebroventricular 
(ICV) reservoir puncture.[3] However, lumbar CSF remains 
the specimen of choice to detect malignant cells of primary 
CNS tumors.[12,16] To avoid false positive results due to 
sloughing of tumor cells at the time of surgery, a recovering 
interval of one to two weeks is currently suggested before 
performing diagnostic postoperative CSF cytologic 
evaluation.[9,16,17] Accurate cytopreparatory techniques 
are essential criteria for successful CSF microscopic 
evaluations. 7.5 mL of CSF are usually withdrawn and 
immediately processed, as the cell counts can diminish by 
up to 50% within 2 h of collection.[4,18] CSF samples are 
then processed by centrifugation (CytospinÒ) at 800 g for 
3-5 min, air-dried for 10-15 min and stained with May-
Grunwald Giemsa (MGG) stain solution for 10-15 min.[19] 
Thin-layer preparation (ThinPrep) is a relatively new 
liquid-based cytology method which has been suggested 
to better detect malignant cells in CSF from solid tumors 
by performing good preservation of cell morphologic 
features. During the ThinPrep analysis, the CSF cells are 
collected through high-precision filtration driven by fluid 
mechanics and gently absorbed onto a glass slide by using 
electrochemical forces. The collected samples need to be 
added to 10 mL preservation solution, mixed and stood 
for 15 min. Slides are fixed in 95% ethanol for 15 min and 
stained by standard Papanicolaou method.[19]
CSF cytology, although indispensable, has many 
limitations Table 2. To start with it involves the pathological 
identification of abnormal cells in the CSF by Giemsa 
stain and clinicians must make judgments on the presence 
or absence of malignant cells. Hence, CSF cytological 
analysis is a pure qualitative test that bears no quantification 
and lacks validation.[3,20] Another weakness is that because 
the shedding of malignant cells into the CSF may occur 
intermittently and in low numbers, inconsistent presence of 
cancer cells in the CSF should be expected. CSF specimens 
may, therefore, fail to capture malignant cells representing 
one of the major weaknesses of CSF cytology. It is therefore 
recommended that CSF analysis should be repeated if 
initially negative.[21] One of the drawbacks is while CSF 
cytology is highly specific in detection of cancer cells, it 
suffers from a lack of sensitivity. A retrospective meta-
analysis[22] reported that CSF cytology sensitivity could be 
as low as 45% depending on how many times the lumbar 
puncture was repeated. False negative cytopathology is 
common (10-20% of patients) because of the paucity of 
cells in the CSF and morphological similarities between 
benign and malignant cells.[13,23,24] The lack of standardized 
techniques for obtaining and evaluating CSF cytology 
specimens and the absence of molecular analysis of tumor 
cells certainly contributes to the wide sensitivity range.[3] 
Hence although it is currently used in the clinic, CSF 
cytology remains a poor surrogate marker for disease 
response in brain cancer/metastasis involvement.[9,13]
Flow cytometry analysis
CSF fluid flow cytometry is a useful addition to CSF 
cytology. Cytology examines morphologic patterns, and 
flow cytometry has the potential to provide information 
about cell surface protein expression. It is an additional 
highly sensitive cytological technique capable of accurately 
Table 1: Association between primary brain tumors localisation and LS incidence
Disease Localisation Incidence LS Source
Medulloblastoma Fossa posterior possible extension to fourth ventricle, brainstem, cisterna magna 30-40% [17,85]
Supratentorial PNETs Frontal lobes, parietal, temporal and occipital lobes 25-40% [17,86]
CNS AT/RT The exact incidence of CNS AT/RT is difficult to determine because the tumor has been widely recognized for only the last decade 29% [87-89]
Retinoblastoma Retina, possible optic nerve invasion and choroidal involvement 3-23% [90,91]
Germ-cell tumors Pineal-region, possible extension to third ventricle, suprasellar 22% [92]
Primary CNS lymphoma Cerebral hemisphers, basal ganglia, corpus callosum, cerebellum 10-20% [93]
Brainstem glioma Tectal plate to medullary cervical junction, possible extension to prepontine cistern and fourth ventricle 3-13% [94,95]
Pinealoblastoma Pineal-region 10% [96]
LGG hypothalamic LGG can occur anywhere in the CNS 7% [97-100]
Ependymoma Infratentorial intraventricular (fourth ventricle’s floor, lateral walls, roof) or supratentorial within the brain parenchyma 5% [17]
LS: leptomeningeal spread; PNETs: primitive neuroectodermal tumors; CNS: central nervous system; AT/RT: atypical teratoid/
rhabdoid; LGG: low-grade glioma
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detecting malignant CSF cells, especially in comparatively 
smaller CSF volume and in samples with very low cell 
counts when combined with multicolor fluorescent antibody 
labelling.[9,23] In this method CSF must be processed 
similar to cytology within 1 hour of sampling however 
centrifugation should be minimized.[14,23] Automated 
methods allow rapid flow cytometry data analysis and 
thereby reduce the significant time expenditures used in 
conventional cytology routine.[14,25] Flow cytometry seems 
to provide a higher sensitivity. However the cell count and 
the percentage of neoplastic cells reported in the CSF by 
both cytology and flow cytometry were significantly higher 
compared with those found to be positive by flow cytometry 
alone.[23]
It has to be said that both false negative and false positive 
results (especially at low cell counts, < 25 cells/uL) can 
occur with flow cytometry too, a poor differential ability 
between mitoses and neoplastic cells is also reported Table 
2. Therefore before flow cytometry can be recommended 
in a routine CSF examination in combination with the 
conventional cytology, standardized protocols are needed 
to uniform definitions of positivity and procedure.[14,23,25] 
Rare cell capture technology, for example, CellSearch® is 
a recent technique using molecular markers to detect and 
enumerate circulating tumor cells in the CSF. This method is 
established to detect prognostic marker on different cancer 
cells circulating in the peripheral blood such as breast 
cancer and has recently attracted the interest of CSF cancer 
researcher.[3,9] However, the application of CellSearch® 
technology for detecting primary CNS cancer cells in CSF 
has not been published yet.
Other tools for cancer cell detection in the CSF
Measuring the chromosomal content of cancer cells in 
the CSF, using DNA single cell cytometry techniques 
or fluorescence in-situ hybridization that detects genetic 
aberrations as a sign of malignancy, can also give additional 
diagnostic information to CSF analysis, but still has a low 
sensitivity Table 2. PCR can also establish cancer diagnosis 
when cytology is inconclusive, but the genetic alteration of 
the neoplasia must be known for it to be amplified with this 
technique, and this is generally not the case.[26]
PROTEOMIC ANALYSIS OF CSF
Proteomic profiling has become an active area of research 
for the biomarker discovery and the identification of new 
targets for therapeutic strategies. Recent studies have 
shown that specific proteomic patterns can differentiate 
subtypes or grades of human brain tumors.[27-30] Modern 
technological advancements in protein quantification which 
Table 2: Advantages and disadvantages of different methods for brain tumors biomarkers detection in the 
CSF
Approach Method Pros Cons
Detection of cancer 
cells in the CSF
CSF cytoanalysis: CSF 
is examined under a 
microscope to look for 
cancer cells
Highly specific[12-14,16]
Low sensitivity and false negative 
results are common[3,13,20,23,24]
Flow cytometry analysis: 
Have the potential to 
provide information 
about cell surface protein 
expression
Automated method that allows 
rapid analysis[14,25]
Smaller CSF volume is needed[9,23]
False negative and false positive 
results can occur (especially at low 
cell counts, < 25 cells/uL).
Poor differential ability between 
mitoses and neoplastic cells is 
reported[14,23,25]
Other tools: Measuring 
chromosomal content of 
cancer cells in the CSF 
using DNA single cell 
cytometry techniques 
or fluorescence in-situ 
hybridization
These techniques have the ability 
to detect genetic aberrations as a 
sign of malignancy location[26]
Low sensitivity[26]
Detection of 
biochemical molecules 
secreted by cancers to 
the CSF
CSF proteomic analysis: 
Systematic identification 
and quantification of the 
complete complement of 
proteins in the CSF
Specific proteomic patterns can 
differentiate subtypes or grades of 
specific brain tumors[27-30]
Limited sensitivity and specificity[31]
CSF microRNAs analysis: 
Measuring microRNA 
Profiling of CSF
High specificity and chemical 
stability[60,101] Only small amounts 
of CSF samples are required for the 
detection of miRNAs in the CSF 
offers the advantage of convenient 
repetitive monitoring of molecular 
events happening in cancer in the 
response to treatment[76]
The unknown origin and factors 
influence their level of expression 
might impact their specificity as 
biomarkers[76,102-106]
CSF: cerebrospinal fluid
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provide rapid screening, low sample consumption, and 
accurate protein identification, have enhanced the precision 
of proteomic analyses and are anticipated to accelerate 
brain tumor biomarker discovery.[31]
Research work on traditional sampling sources for 
proteomic profiling, such as blood[31,32] and tissue lysates,[33] 
have yielded asubstantial amount of information on 
potential brain cancer biomarkers. However, the majority of 
these markers exhibited limited value in a clinical setting, 
justifying the need for the exploration of more clinically 
relevant sampling sources. One such a promising source 
for protein biomarker discovery is the CSF where protein 
presences might result from either secretion/leaking by 
tumor tissues or abnormal blood brain barrier function.[8]
CSF proteomic analysis for detection of brain 
cancer markers
In the search for accurate biomarkers a number of reports 
have emerged over the past decade describing the analysis of 
different brain cancer proteome using CSF. For example the 
CSF level of carcinoembryonic antigen (CEA), is a protein 
tumor marker that is commonly increased in several human 
malignances, was found recently to play an important 
role in differential diagnosis of primary and metastatic 
brain tumors[34,35] and useful auxiliary marker in diagnosis 
of meningeal carcinomas.[36-38] In a study by Khwaja et 
al.,[39]the authors reported that proteomic analysis of CSF 
can discriminate malignant and non-malignant disease of 
the CNS and identified carbonic anhydrase protein (known 
to be overexpressed in many malignancies including high-
grade gliomas) as a prognostic marker of brain cancer.
The most significant example of how analysis of CSF 
proteins has impacted the clinical management of CNS 
cancer is in the case of intracranial malignant germ cell 
tumors.[40] Germ cell tumors are heterogeneous group of 
gonadal or extragonadal tumors that thought to arise from 
the aberrant migration and differentiation of primordial 
germ cells during embryogenesis. Extragonadal germ cell 
tumors can occur intracranial in the pineal and suprasellar 
regions and comprise approximately 3% of all pediatric 
brain tumors. Germ cell tumors retain the molecular 
characteristics of their primordial lineage as they maintain 
the expression of embryonic proteins, such as beta human 
chorionic gonadotropin (bHCG) and alpha-fetoprotein 
(AFP).[41] bHCG is a 36 kDa glycoprotein normally secreted 
by placental tissues while AFP is a 70 kDa glycoprotein 
normally secreted by the foetus primarily in the yolk sac, 
gastrointestinal tract, and liver. AFP is elevated in wide 
range of cancers, including colon adenocarcinoma, liver 
and gastric cancers while bHCG and AFP were found to 
be markedly elevated in the CSF of intracranial malignant 
germ cell tumor patients.[42] Both markers are currently 
utilized clinically as diagnostic and accurate indicators of 
response to therapy. Assessment of AFP and total bHCG in 
both serum and CSF is mandatory in order to distinguish 
between germinoma and NGGCT non-germinoma germ 
cell tumors. CSF AFP > 1000 ng/mL at diagnosis, or age 
< 6 years, intracranial malignant germ cell tumor patients 
are stratified as high risk and are treated more intensively. 
Moreover, the verification of bHCG and AFP levels prior 
to surgical resection provides a reference point that can be 
used to assess recurrence during follow-up however their 
absence does not rule out a germ cell tumor. Additional 
CSF protein markers such as placental alkaline phosphatase 
(PLAP) and lactate dehydrogenase isoenzymes have 
been shown to be clinically useful in the diagnosis and 
monitoring of pediatric intracranial germinomas, however 
such markers are less specific.[43] Elevated levels of s-kit, the 
soluble form of the c-kit receptor, a transmembrane tyrosine 
kinase receptor, was found to be a reliable marker for germ 
cell tumor diagnosis that can differentiate germ cell tumors 
from other CNS cancers. Miyanohara and colleagues also 
reported that s-kit expression is able to detect recurrence of 
germ cell tumors and subarachnoid dissemination.[44]
Gliomas are the most common primary brain tumors in 
adults. Glioblastoma multiforme (GBM) is the deadliest 
glioma with a median survival of only 14 months despite 
the recent advances in intensive therapeutic strategies.[45] 
Hence more effort was applied to study whether specific 
CSF proteomic profile can be generated to evaluate gliomas 
prognosis. Fang Shen et al.[8] conducted a review of the 
literature on the proteomic screening for glioma-related 
protein biomarkers in CSF. They were able to identify 19 
differentially expressed proteins, the majority exhibited 
increased concentrations (B2M, CA2, CA12, CALD1, 
DDAH1, MYCN, PPIA, SPP1, VEGFB, ALB, MAPT, 
SERPINA3, SPARCL1) while (GSN) was downregulated 
in the glioma CSF. Further functional assessments revealed 
several important protein networks (e.g., IL6/STAT-3) and 
four novel focus proteins (IL-6, galanin (GAL), HSPA5 and 
WNT4) and the authors reported that these proteins might 
be involved in glioma pathogenesis. On the same theme, 
Khwaja and colleagues used two proteomic techniques, 
two-dimensional gel electrophoresis and cleavable Isotope-
Coded Affinity Tag to compare CSF proteomes in order to 
identify tumor- and grade-specific biomarkers in patients 
bearing brain tumors of different histology and grades. By 
performing retrospective analyses on 60 samples derived 
from astrocytomas WHO grade II, III, and IV, schwannomas, 
metastastic brain tumors, inflammatory samples, and non-
neoplastic controls, the group identified 103 potential 
tumor-specific markers of which 20 were high-grade 
astrocytoma-specific.[46] SPARCL1, FGF14, VEGF-B, tau, 
b2M, bdefensin and Attractin were found as an upregulated 
marker in the CSF of patients with malignant astrocytoma and 
mediates glioma cell migration.[47] Sampath et al. assessed 
whether vascular endothelial growth factor (VEGF) could 
be measured in the CSF of patients with cerebral neoplasms 
and used as a marker of particular brain cancer tumors. 
They investigated CSF samples from 27 patients with high-
grade astrocytomas, 39 patients with nonastrocytic CNS 
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neoplasms, and 14 patients with no known CNS neoplasm. 
In their study, VEGF was detectable in 89% of samples 
with malignant astrocytoma and not normal CSF samples. 
The levels of VEGF were significantly higher in high-grade 
astrocytomas than in nonastrocytic tumors indicating that 
detection of VEGF in CSF could be a potential marker for 
differentiating astrocytic from nonastrocytic tumors.[48]
Another group applied mass spectrometry based technology 
to identify possible CSF peptide markers of GBM.[49] 
Out of 2,000 detected CSF peptides four peptides which 
significantly distinguished GBM from controls were 
identified. They were specific C-terminal fragments of 
alpha-1-antichymotrypsin, osteopontin, and transthyretin 
as well as N-terminal residue of albumin. Interestingly 
the identified four molecules are constituents of normal 
CSF, but this group are the first to report their significant 
elevation in CSF of GBM patients. To detect biomarkers 
in high-grade astrocytomas, Ohnishi and colleagues 
analysed the differential expression of proteins in the 
CSF from two cases each of diffuse astrocytoma (grade 
II), and glioblastoma (grade IV) using agarose 2-D gel 
electrophoresis. The authors found that the expression of 
gelsolin protein is decreased with histological grade. To 
examine whether gelsolin is a useful indicator of tumor 
aggressiveness the group further analysed the gelsolin 
expression in 41FFPE astrocytomas. Gelsolin expression 
was found to be significantly lower in high-grade than in 
low-grade astrocytomas. Moreover the overall survival of 
patients in the low-gelsolin expression was significantly 
poorer than in the high expression group highlighting the 
usefulness of gelsolin as a potential prognostic factor in 
astrocytoma.[31,50]
Diffuse intrinsic pontine glioma (DIPG) is not surgically 
resectable, resulting in a paucity of tissue available for 
molecular studies and, currently, there are no effective 
treatments. Saratsis et al. investigated 15 CSF specimens 
from patients with DIPG for proteomic analysis. Protein 
profiling was generated by mass spectrometry. CSF 
proteomic analysis revealed selective upregulation of 
Cyclophillin A (CypA) and dimethylarginase 1 (DDAH1) 
in DIPG, compared with controls. Protein expression 
was further validated with Western blot analysis and 
immunohistochemical assays using CSF and brain tissue as 
well as in blood samples from DIPG. Immunohistochemical 
staining showed selective upregulation of secreted but not 
cytosolic CypA and DDAH1 in patients with DIPG. Their 
study indicated that detection of secreted CypA and DDAH1 
in CSF and serum has potential clinical application, with 
implications for assessing treatment response and detecting 
tumor recurrence in patients with DIPG.[51]
Primary central nervous system lymphoma (PCNSL) is 
another highly aggressive tumor that can lead to quick 
death if not diagnosed in time. The diagnosis of PCNSL can 
present a diagnostic challenge. It relies on histopathology 
of brain biopsies to the same extent as most brain tumors, 
while less invasive tests to detect early tumor pathogens 
with sufficient diagnostic accuracy are not available yet. 
Proteomic analysis of CSF has revealed various proteins 
that are differentially expressed in CNS lymphoma.[52-54] 
Among these, antithrombin III (ATIII), a serine protease 
inhibitor that is associated with neovascularization in CNS 
lymphoma, has been prospectively validated.[26] ATIII 
expression was reported by Roy et al.[55] to be elevated in 
the CSF of patients with CNS lymphoma compared to those 
patients with control. ATIII levels higher than 1.2 g/mL 
made the detection of CNS lymphoma possible with >70% 
sensitivity and 99% specificity.[26] Elevated antithrombin 
III levels significantly correlated with shorter survival rates 
and less response to chemotherapy. However and on the 
contrary a recent study from Finland, by Kuusisto et al.[56] 
declared that ATIII is not a suitable biomarker for diagnosis 
of PCNSL and increased concentrations of ATIII in CSF 
might be due to leakage of the blood-brain barrier.[57]
CXCL13 protein that is known to mediate chemotaxis of 
CNS lymphoma cells was detected within biopsy specimens 
from PCNSL patients[58] raising the possibility that this 
chemokine may contribute to CNS tropism. Rubenstein 
and colleagues investigated the concentration of CXCL13 
in CSF of CNS lymphoma patients and control cohorts 
in a multicenter study involving 220 patients. Their result 
demonstrated that elevated CXCL13 concentration in 
CSF is a highly specific marker for the detection of CNS 
lymphoma and can be helpful as an adjunctive diagnostic 
test and response to treatment assessment. Following their 
steps in studying chemokine in PCNSL, Sasagawa et al. 
investigated CSF from 19 patients with CNS lymphoma (15 
and 26 non-lymphoma patients with various brain tumors) 
and reported that CSF IL-10 is a superior biomarker for 
initial screening for patients with CNS lymphoma.[59]
Medulloblastoma (MB) is the most common malignant 
brain tumor in children. It includes various subtypes with 
group 3 and 4 subtypes being clinically distinct with regard 
to metastasis and prognosis, which may also manifest in 
a difference in their proteomic spectra. With the aim to 
identify putative biomarkers for MB in CSF, Rajagopal et 
al.[60] investigated the CSF proteome from 33 children with 
MB and compared it against the CSF proteome from 25 age-
matched controls using two-dimensional gel electrophoresis. 
In their study levels of prostaglandin D2 synthase (PGD2S) 
were found to be six-fold significantly decreased in the CSF 
of tumor samples most likely representing a host response 
to the presence of the tumor.[61] Usually biomarkers are 
often thought to be elevated in a disease state compared 
to normal levels however candidate negative diagnostic 
marker such as PGD2S could be useful for detecting MB 
as well as recurrence of the disease. On the other hand it 
has to be said that while negative biomarkers are potentially 
useful, their relationship to tumor biology is less direct and 
more highly complex in comparison to proteins that are 
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over-expressed in tumor associated samples.[40] Desiderio 
et al.[62] investigated CSF from 14 children with posterior 
fossa tumors (6 Pilocytic astrocytoma, 5 Medulloblastoma, 
3 Ependymoma and 5 nontumoral control). In their study the 
CSF proteomics demonstrated the potential biomarker role 
of the hemoglobin subunit beta fragments (peptides LVV- 
and VV-hemorphin-7) in posterior cranial fossa pediatric 
brain tumors. Both LVV- and VV-h7 were detectable in 
control-CSFs but absent in the patient CSFs collected 
before surgery (i.e. in presence of tumor). Interestingly 
both LVV- and VV-h7 were also absent in the CSF collected 
6 days after the resection tumor in patients with tumor 
relapse. Their data suggest that analysis in post-surgery 
CSF could be used to predict patient prognosis. However, 
it will be interesting to evaluate the cancer specificity of 
LVV- and VV-h7 in relation to other forms of CNS pediatric 
tumors. Finally levels of polysialic-neural cell adhesion 
molecule (PSANCAM), considered a marker of developing 
neuron, were found to be significantly higher in CSF from 
MB patients that are refractory to treatment or those who 
relapsed, than patients in remission.[63]
Atypical teratoid/rhabdoid (AT/RT) tumor is a rare, highly 
malignant tumor of the CNS most commonly found in 
children less than 5 years of age. Osteopontin (OPN) a bone 
matrix glycoprotein levels were found to be significantly 
elevated in patients with AT/RT. Clinical studies identified 
OPN as a potential diagnostic marker in ovarian, breast, 
colon, prostate, and lung cancers.[64] Using enzyme-linked 
immunosorbent assay and immunohistochemical analysis, 
Kao et al.[65] investigated plasma, CSF, and brain tissue 
specimens from 39 patients MB, 16; AT/RT, 8; epilepsy, 6; 
hydrocephalus, 9) and found that patients with AT/RT have 
higher plasma and CSF OPN levels in comparison with 
patients with MB, hydrocephalus, or epilepsy. Interestingly 
significant correlation between OPN levels and the risk of 
tumor relapse in patients with AT/RT was identified while 
OPN levels in the CSF were found to decrease with treatment.
Other biochemical markers
Malignant brain tumors may show an increased fraction of 
anaerobic LDH concentrations (LD4 and LD5) in CSF.[52] A 
number of other potential CSF protein biomarkers for CNS 
cancers have been reported in the literature such as Insulin-
like growth factor binding protein 2 (IGFBP2), Insulin-like 
growth factor binding protein 3 (IGFBP3),[66] Polysialic-
neural cell adhesion molecule (PSANCAM),[63] Total 
Tau (t-Tau),[67] Tumor necrosis factor (TNF) alpha[68] and 
CSF , S-100,[69] Neuron-specific (NSE),[70] neuron growth 
factor, HCG.[71] Apolipoprotein A-II,[72] MIC-1/GDF15,[73] 
Elevated expression of such markers in the CSF was found 
to be relatively specific for brain cancer[74,75] however 
sensitivities and specificities have widely varied.[26]
MICRORNAS
MicroRNAs (miRNA) are short, non translated fragments 
of RNA that bind to 3’ untranslated regions of messenger 
RNA and repress protein translation in several molecular 
pathways.[26] The discovery of miRNAs role in controlling 
essential regulators of key pathways implicated in 
development of CNS tumors make them a powerful tool for 
detection of cancer, risk assessment and prognosis. During 
the past decades, great efforts have been made in conducting 
research evaluating the diagnostic value of miRNAs in 
CNS cancer’s tissue.[76] However, a major drawback of 
the tissue-based approach centers on the need for invasive 
surgical procedures in sample collection. MiRNAs have 
been found to stably coexist in several body fluids including 
CSF which can be collected with minimal invasiveness and 
permit following the disease over time.[26] In this context 
several reports have described that deregulated miRNAs in 
CSF are closely associated with the clinical course of CNS 
malignant tumors.[2,77-82]
For example Baraniskin et al.[77] found that combined 
expression analyses of miR-21 and miR-15b were able to 
distinguish patients with glioma from controls with various 
neurologic disorders, including patients with carcinomatous 
brain metastases and primary CNS lymphoma with accuracy 
of 90% sensitivity and 100% specificity. While Teplyuk 
and colleagues[2] reported that combined analysis of a 
group of seven CSF miRNAs enabled the discrimination 
between GBM and metastatic brain cancers with more than 
90% accuracy. miRNA-21 and miR-10b expression levels 
were significantly increased only in brain tumor lesions 
(in patients with GBM or brain metastases) compared to 
nonneoplastic conditions while members of the miR-200 
family were found solely in CSF of patients with brain 
metastases, indicating that CSF miRNAs could be used to 
discriminate between glioblastoma and metastatic brain 
tumors, an important consideration for cancer treatment.[2] 
GBM is the deadliest glioma with median survival of 
only 14 months despite the recent advances in intensive 
therapeutic strategies.[80] Due to their anatomic location 
and infiltrative nature, these tumors are not amenable to 
surgical resection or even to biopsy in some cases. The 
paucity of biomarkers represents a sizable gap in improving 
the clinical management of these patients. Analysis of CSF 
miRNA could therefore be advantageous for identifying 
putative disease markers for DIPGs.
An earlier work by Baraniskin and colleagues demonstrated 
that combined miRNA analysis of miR-19, miR-21, and 
miR-92a in CSF accurately discriminate patients with 
PCNSL from other neurologic disorders controls with 
diagnostic accuracy of 95.7% sensitivity and 96.7% 
specificity indicating significant diagnostic value.[77] In the 
same theme Scott et al. conducted a review of the literature 
on CNS lymphoma diagnosis (1966 to 2011) and extracted 
data regarding the usefulness of CSF cytology, proteomics 
and miRNAs in the diagnosis of CNS lymphoma. The 
authors reported low sensitivity for CSF cytology (2-32%) 
which is increased when combined with flow cytometry. 
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CSF lactate dehydrogenase isozyme 5, β2-microglobulin, 
and immunoglobulin heavy chain rearrangement studies 
have improved sensitivity over CSF cytology (58-85%) but 
have only moderate specificity (85%). Interestingly miRNA 
analysis has more than 95% specificity in the diagnosis of 
CNS lymphoma.[79]
Twenty three studies with a total of 299 CNS cancer 
patients and 418 controls were analyzed by Wei et al.[81] 
through systematic meta-analysis for articles in the 
topic diagnostic value of miRNAs for CNS cancers and 
comparing sensitivity of on blood-and CSF based miRNAs 
assays for the diagnosis of CNS malignancies. Thirteen 
out of the 23 studies they analyzed focused on miRNAs 
as diagnostic biomarkers for glioma and 10 for PCNSL 
detection. The performance of miRNAs in CSF for CNS 
cancers detection showed more correctness in sensitivity 
suggesting a relatively high diagnostic accuracy. By the end 
of the study the authors concluded that miRNAs may be 
suitable as biomarkers for CNS cancers detection and that 
the CSF based miRNAs assays could be considered more 
reliable for clinical application. However, further validation 
based on a larger sample of patients and controls is still 
required.[81]
The presence and biological role of miRNAs in the 
extracellular environment of meddulloblastoma MB was 
examined recently by our lab and we found that more than 
one thousand miRNAs were released in the culture-medium 
in each of the MB cell lines tested.[82] Among them a panel of 
miRNAs were specific to the culture-medium of metastasis-
related cell lines (D341 and D283) which represents the 
aggressive group 3 and group 4 MB subtypes. Interestingly, 
three metastasis-associated miRNAs were over-represented 
in culture-medium of metastasis-related MB cell lines were 
found to be significantly enriched in the CSF of the MB 
patient. Although more samples are required to fully verify 
these results, our work presented the first evidence for the 
presence of miRNAs excreted extracellularly by MB cells 
and raises the possibility that investigations, using larger 
sets of MB samples, could lead in the near future to the 
discovery of CSF-derived miRNA markers, with diagnostic 
and prognostic significance.
HOW NEAR ARE WE TO USING CSF 
MOLECULAR MARKERS FOR BRAIN 
CANCER DIAGNOSIS IN THE CLINIC?
The promise of CSF biochemical markers Table 3, such as 
proteins and miRNA, to detect and monitor brain cancer has 
swept through the oncology research area in recent years 
leading to ample publications. However, most putative 
markers did not progress beyond their initial discovery. 
A striking discrepancy exists between the effort directed 
toward CSF biomarker, whether it is protein or miRNA, 
discovery and the number of markers that made it into 
Table 3: CSF biomarkers for the detection of brain cancer
Brain cancer Marker Method of detection References
Medulloblastoma, primitive neuroectodermal 
tumors, germ cell tumors, ependymoma and 
glioma
Cancer cells CSF cytology [12-14]
Intracranial malignant germ cell tumors bHCG and AFP CSF proteomic analysis [41]
Pediatric brain tumors (medulloblastoma , 
high-grade glioma, atypical rhabdoid tumor, 
astrocytoma, plexus carcinoma and anaplastic 
ependymoma, germ cell tumor)
Apolipoprotein A-II CSF proteomic analysis [72]
CNS lymphoma CD27, AT III, chemoattractant, CXCL13, CXCL12 and IL10 CSF proteomic analysis [55,57,107-111]
Cerebral low-grade lymphoma Immunoglobulin G IgG CSF proteomic analysis [112]
Brain metastases from lung adenocarcinoma Epidermal growth factor receptor 
EGFR
CSF proteomic analysis [113]
Brain metastases from lung and breast cancers VEGF and stromal cell derived 
factor (SDF)-1
CSF proteomic analysis [73]
Medulloblastoma PGD2 CSF proteomic analysis [60]
Meningeal carcinomas CYFRA 21-1, NSE and CEA CSF proteomic analysis [70]
Glioblastoma MIC-1 GDF15 CSF proteomic analysis [114]
Glioblastoma miR-21 and miR-15b CSF microRNA analysis [115]
PCNSL miR-19, miR-21, and miR-92a CSF microRNA analysis [115]
Glioblastoma and brain metastasis miR-10b and miR-21 CSF microRNA analysis [116] [117]
Brain metastases from lung and breast cancers Members of miR-200 family CSF microRNA analysis [116]
Glioblastoma, medulloblastoma, brain 
metastasis and lymphoma
miR-935, miR-451, miR-711, 
miR-223 and miR-125b CSF microRNA analysis [118]
CSF: cerebrospinal fluid; PCNSL: primary central nervous system lymphoma; bHCG: human chorionic gonadotropin; AFP: alpha-
fetoprotein; AT III: antithrombin III; CXCL13: chemokine C-X-C motif ligand 13; IL10: interleukin 10; VEGF: vascular endothelial 
growth factor; PGD2: Prostaglandin-D2 synthase; CYFRA 21-1: cytokeratin-19 fragment; NSE: neuron-specific enolase; CEA: 
carcinoembryonic antigen; MIC-1: macrophage inhibitory cytokine-1; GDF15: growth differentiation factor 15
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clinical practice.[83] Understanding the reasons why the 
role of these markers is not yet established in the diagnosis 
of CNS tumors can help accelerate the conduit between 
their discovery and clinical implementation. One of the 
confounding issues that participate in the failure of potential 
markers to reach the clinic is the lack of reproducibility 
between similar studies or low correlation of results. 
The most significant source for such inter-laboratory 
discrepancies is mainly due to differences in protein/miRNA 
preparation, in the analytical methods or the use of different 
technologies which may bias the analysis. There are various 
platforms/techniques which exist each with specific biases 
that can greatly influence the relative expression of certain 
molecules in the tested CSF sample and may lead to foregone 
conclusions. No wonder there is often a low correlation of 
results obtained from different platforms or even from the 
same labs using kits and reagents from different vendors. 
Yet there are no universally implemented guidelines. Hence 
standardization of these assays including CSF handling 
(collection, storage and preparation) is a challenge for the 
near future. Teuniseen et al.[84] have proposed protocols for 
the standardization of CSF collection to minimizing blood 
contamination of CSF and protocols for the standardization 
of CSF storage to prevent sample degradation and global 
proteome changes.[40]
Another critically important consideration is that despite 
the fact that several advanced platforms are available the 
analysis of secreted proteins/miRNA in the CSF is still a 
very challenging task due to technical difficulties. Often the 
scientists working on CSF biomarker discovery have limited 
knowledge of the protein/miRNA isolation/detection new 
platforms and or the analytical requirements which may 
hamper the subsequent markers analysis.
Together with low sample numbers that usually result in 
inadequate statistical power is another general weakness 
and might explain why not many of these markers have 
been validated for clinical use.[31,40] Taking together the 
successful translation of CSF biomarkers from basic 
research to clinical applications will likely require multi-
centre standardized and coordinated efforts to facilitate 
biomarkers discovery and implementation. Finally there are 
some other limitations to the interpretation of CSF cancer 
related molecules studies as biomarker. Protein/miRNA 
composition of CSF is dependent on patient attributes such 
as age, gender, the specific site of CSF access.[40]
CONCLUSION
CSF is an invaluable diagnostic window to the pathological 
state of CNS. It is easily accessible by minimally-invasive 
standard clinical methods and can provide the necessary 
biological information for the diagnosis of neurological 
diseases. Biochemical molecules secreted by brain cancers 
to the CSF hold great promise as diagnostic markers 
for a wide range of brain malignancies owing to the 
significant differences that have been reported between 
their expression profiles in healthy individuals and those 
of patients. However, significant concerns remain. Despite 
the sizeable published number of potential diagnostic and 
prognostic CSF biochemical markers their reproducibility 
between studies is unclear, and none have been validated 
for clinical use. The reported sample size in the literature 
is small. Most data were generated by a limited number of 
research groups using different protocols or technologies. 
No universally implemented guidelines are available yet for 
the CSF sample collection and preparation or for protein 
profiling or miRNA extraction from CSF and importantly 
for data analysis. It is therefore premature to make specific 
recommendations for their clinical implementation. More 
research that includes multi-institutional research and 
longitudinal studies of large patient cohorts to validate the 
clinical value of putative CSF markers, as demonstrated 
for the field of cancer genomics, is certainly warranted. 
The road from CSF biomarker discovery, validation, until 
the translation into the clinical setting could be long and 
difficult however, the reward for patients, clinicians and 
scientists could be rather significant.
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